- Home
- RELX vs GNLX Comparison
RELX vs GNLX Comparison
Compare RELX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELX | GNLX |
|---|---|---|
| Founded | 1903 | 2001 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.0B | 110.4M |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RELX | GNLX |
|---|---|---|
| Price | $34.73 | $2.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.7M | 309.8K |
| Earning Date | 02-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | $8.72 | N/A |
| Revenue Next Year | $6.41 | N/A |
| P/E Ratio | $20.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.57 | $2.29 |
| 52 Week High | $48.40 | $8.54 |
Technical Indicators
Market Signals| Indicator | RELX | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 38.35 |
| Support Level | $32.30 | $2.33 |
| Resistance Level | $35.73 | $2.97 |
| Average True Range (ATR) | 0.62 | 0.15 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 21.43 | 15.18 |
Price Performance
Historical ComparisonAbout RELX RELX PLC PLC
RELX is a developer of information-based analytics and decision tools designed to support research, risk assessment, legal work, and business operations. The company offers data analytics, scientific and technical information resources, legal research tools, and event management platforms. This enables professionals, researchers, legal teams, and businesses to make informed decisions and improve operational efficiency.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.